An Overview of CIDP
Dr Lewis gives a comprehensive overview of CIDP and describes the most common symptoms seen in patients.
EP: 1.An Overview of CIDP
EP: 2.Defining 'Typical' and 'Atypical' Variants of CIDP
EP: 3.Diagnosing CIDP
EP: 4.Red Flag Symptoms of CIDP
EP: 5.Current Treatment Landscape of CIDP
EP: 6.Effects on Quality of Life and Unmet Needs of CIDP
EP: 7.Emerging Agents for Treatment of CIDP
EP: 8.Clinical Pearls for HCPs Diagnosing CIDP
This is a video synopsis/summary of a panel discussion involving Richard Lewis, MD.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated condition characterized by nerve damage affecting various parts of the body. Richard Lewis, MD, emphasizes the significance of each term in CIDP, where "chronic" denotes progression over eight weeks, "inflammatory" indicates an immune-mediated process, and "demyelinating" involves insulation loss in nerves. The term "polyneuropathy" highlights the condition's impact on multiple nerves, affecting sensation and strength.
Dr Lewis describes typical CIDP manifestations as symmetric weakness in both proximal and distal muscles, with early reflex loss. The cause remains unknown, and CIDP presents in various forms, including atypical variants. Antibodies appear involved in about 10% of patients, and T-cells may play a role. Lewis mentions a recent phase two trial involving a neonatal Fc receptor (FcRn) inhibitor, suggesting that IgG (immunoglobulin G) is a significant factor in CIDP. He notes the evolving understanding of CIDP, with some elements now recognized as separate entities. The discussion underscores the complexity of CIDP, involving multiple immune components and the need for further research to unravel its intricacies.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
